Logo

Exagen: Tina Nova

Jan 23, 2023

Exagen has elected Tina Nova as executive chair of its board of directors. Nova succeeds Brian Birk, who served as chair of the board since 2018 and will remain as a board member.

Nova currently serves as president of Veracyte's CLIA business. She was previously president and CEO of Decipher Biosciences until March 2021, when Veracyte acquired Decipher. Nova has also been CEO of Molecular Stethoscope and senior VP and general manager of oncology at Illumina. She was the cofounder, president, and CEO of Genoptix, which was acquired by Novartis in 2011. Nova also serves on the board of Azenta and has been a board member with Veracyte and Arena Pharmaceuticals. She holds a PhD in biochemistry from the University of California, Riverside and a BS in biological sciences from UC Irvine.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.